{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-046889","form_type":"8-K","ticker":"CRSP","cik":"0001674416","company_name":"CRISPR Therapeutics AG","filed_at":"2023-09-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.812420+00:00","generated_at":"2026-06-10T22:52:27.579714+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"CRISPR Therapeutics President & Chairman Novak to resign Sept 15; CEO Kulkarni to become Chairman","bullets":["Rodger Novak resigns as President and Chairman, effective September 15, 2023; no dispute or disagreement cited.","Samarth Kulkarni, Ph.D., CEO, appointed Chairman of the Board effective same date; will continue as CEO.","Novak co-founded CRISPR nearly 10 years ago, was instrumental in key collaborations and exa-cel development.","Kulkarni's compensation arrangement remains unchanged; Board thanks Novak for his leadership.","CRISPR's exa-cel for sickle cell disease and beta thalassemia is under regulatory review for potential first CRISPR-based medicine approval."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-046889","json":"https://secwatch.observer/filing/0000950170-23-046889.json","markdown":"https://secwatch.observer/filing/0000950170-23-046889.md","text":"https://secwatch.observer/filing/0000950170-23-046889.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674416/000095017023046889/0000950170-23-046889-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674416/000095017023046889/crsp-20230904.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T22:52:27.579714+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"150c1a982c","claim":"Rodger Novak resigned as President and Chairman at CRISPR Therapeutics AG.","evidence_excerpt":"On September 7, 2023, CRISPR Therapeutics AG (the “Company”) announced that Rodger Novak, M.D. tendered his resignation as President of the Company as well as a director and Chairman of the Company’s Board of Directors (the “Board”), and all such resignations to be effective as of September 15, 2023 (the “Resignation Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1674416/000095017023046889/0000950170-23-046889-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President and Chairman"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}